CN116723858A - 图卡替尼联合曲妥珠单抗、紫杉烷和vegfr-2拮抗剂治疗her2阳性癌症的方法 - Google Patents

图卡替尼联合曲妥珠单抗、紫杉烷和vegfr-2拮抗剂治疗her2阳性癌症的方法 Download PDF

Info

Publication number
CN116723858A
CN116723858A CN202180060011.7A CN202180060011A CN116723858A CN 116723858 A CN116723858 A CN 116723858A CN 202180060011 A CN202180060011 A CN 202180060011A CN 116723858 A CN116723858 A CN 116723858A
Authority
CN
China
Prior art keywords
subject
cancer
administered
trastuzumab
paclitaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180060011.7A
Other languages
English (en)
Chinese (zh)
Inventor
L·沃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sijin Co
Original Assignee
Sijin Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sijin Co filed Critical Sijin Co
Publication of CN116723858A publication Critical patent/CN116723858A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202180060011.7A 2020-07-29 2021-07-28 图卡替尼联合曲妥珠单抗、紫杉烷和vegfr-2拮抗剂治疗her2阳性癌症的方法 Pending CN116723858A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063058146P 2020-07-29 2020-07-29
US63/058,146 2020-07-29
PCT/US2021/043395 WO2022026510A1 (en) 2020-07-29 2021-07-28 Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist

Publications (1)

Publication Number Publication Date
CN116723858A true CN116723858A (zh) 2023-09-08

Family

ID=77666547

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180060011.7A Pending CN116723858A (zh) 2020-07-29 2021-07-28 图卡替尼联合曲妥珠单抗、紫杉烷和vegfr-2拮抗剂治疗her2阳性癌症的方法

Country Status (10)

Country Link
US (1) US20230270745A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188384A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023537676A (cg-RX-API-DMAC7.html)
KR (1) KR20230047359A (cg-RX-API-DMAC7.html)
CN (1) CN116723858A (cg-RX-API-DMAC7.html)
AU (1) AU2021315520A1 (cg-RX-API-DMAC7.html)
CA (1) CA3189333A1 (cg-RX-API-DMAC7.html)
IL (1) IL300052A (cg-RX-API-DMAC7.html)
MX (1) MX2023001233A (cg-RX-API-DMAC7.html)
WO (1) WO2022026510A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
WO2024089702A1 (en) * 2022-10-28 2024-05-02 Natco Pharma Limited An improved process for the preparation of tucatinib and its salt & polymorphs thereof
KR20250139608A (ko) * 2024-03-15 2025-09-23 충북대학교 산학협력단 오시머티닙, 에토포사이드 및 도세탁셀이 봉입된 폴리비닐 카프로락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그래프트 공중합체 마이셀 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032082A (zh) * 2017-04-28 2020-04-17 西雅图基因公司 Her2阳性癌症的治疗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
KR102000312B1 (ko) 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
US9168254B2 (en) 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
WO2013170263A2 (en) * 2012-05-11 2013-11-14 Merrimack Pharmaceuticals, Inc. Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032082A (zh) * 2017-04-28 2020-04-17 西雅图基因公司 Her2阳性癌症的治疗

Also Published As

Publication number Publication date
CA3189333A1 (en) 2022-02-03
EP4188384A1 (en) 2023-06-07
JP2023537676A (ja) 2023-09-05
IL300052A (en) 2023-03-01
US20230270745A1 (en) 2023-08-31
WO2022026510A1 (en) 2022-02-03
MX2023001233A (es) 2023-03-02
AU2021315520A1 (en) 2023-02-09
KR20230047359A (ko) 2023-04-07

Similar Documents

Publication Publication Date Title
AU2022241509B2 (en) Treatment of HER2 positive cancers
US20220387618A1 (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
US20240366600A1 (en) Pharmaceutical compositions and use thereof
US20230270745A1 (en) Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
US20230173067A1 (en) Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
CN121311227A (zh) 用于治疗kras依赖性癌症的法尼基转移酶抑制剂
EP4048275A1 (en) Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
WO2022111618A1 (zh) 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物
WO2023230429A1 (en) Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
HK40076724A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
CN114470190A (zh) 喹啉衍生物与pd-1单抗的药物组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination